Deciphera Pharmaceuticals, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2024-06-11: Form 8-K; Period of report 2024-06-11; Description 1.02 Termination of a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events; Details 1.02.
- 2024-04-29: Form 8-K; Period of report 2024-04-29; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
- 2024-02-06: Form 8-K; Period of report 2024-02-06; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2024-01-08: Form 8-K; Period of report 2024-01-08; Description 2.02 Results of Operations and Financial Condition; 8.01 Other Events; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2024-06-11 | 8-K | 2024-06-11 | 1.02 Termination of a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 1.02 Effective as of June 11, 2024 and in connection with the completion of the Merger, the Company terminated its 2015 Equity Incentive Plan, 2017 Stock Option and Incentive Plan, 2022 Inducement Plan, and 2017 Employee Stock Purchase Plan. 2.01 The disclosures under the Introductory Note and Item 3.01 are incorporated herein by reference. 3.01 The disclosures under the Introductory Note are incorporated herein by reference. 3.03 The disclosures under the Introductory Note, Item 1.02, Item 2.01, Item 3.01, Item 5.01 and Item 5.03 are incorporated herein by reference. 5.01 The disclosures under the Introductory Note, Item 1.02, Item 2.01, Item 3.01, Item 5.02 and Item 5.03 are incorporated herein by reference. 5.02 As of the Effective Time, Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera and members of any committee of Deciphera’s board of directors. 5.03 Pursuant to the terms of the Merger Agreement, as of the Effective Time, Deciphera’s certificate of incorporation, as in effect immediately prior to the Effective Time, was amended and restated in its entirety (the “Second Amended and Restated Certificate of Incorporation”). 8.01 The Company previously disclosed that it intended to hold its 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”) on June 20, 2024. | d824393d8k.htm |
| 2024-04-29 | 8-K | 2024-04-29 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On April 29, 2024, the Company issued a press release announcing the execution of the Merger Agreement. | d831713d8k.htm |
| 2024-02-06 | 8-K | 2024-02-06 | 2.02 Results of Operations and Financial Condition | 2.02 On February 6, 2024, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter and fiscal year ended December 31, 2023 and provided a corporate update. | d128290d8k.htm |
| 2024-01-08 | 8-K | 2024-01-08 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On January 8, 2024, Deciphera Pharmaceuticals, Inc. (the “Company”) disclosed that, based on preliminary unaudited financial information, it had preliminary unaudited total revenue of approximately $47 million for the fourth quarter ended December 31, 2023, and approximately $162 million for the full year ended December 31, 2023. | d104319d8k.htm |
| 2023-10-30 | 8-K | 2023-10-30 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On October 30, 2023, Deciphera Pharmaceuticals, Inc. (the “Company” or “we”) announced its financial results for the quarter ended September 30, 2023 and provided a corporate update. 8.01 On October 30, 2023, the Company announced positive top-line data from its pivotal Phase 3 MOTION study of vimseltinib, an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of the colony stimulating factor 1 receptor (CSF1R) in patients with tenosynovial giant cell tumor (TGCT). | d558819d8k.htm |
| 2023-08-09 | 8-K | 2023-08-09 | 2.02 Results of Operations and Financial Condition | 2.02 On August 9, 2023, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2023 and provided a corporate update. | d524915d8k.htm |
| 2023-08-03 | 8-K | 2023-08-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 1, 2023, Daniel L. Flynn, Ph.D., notified Deciphera Pharmaceuticals, Inc. (the “Company”) of his retirement from employment with the Company, effective on December 31, 2023, and his resignation from his position as Executive Vice President, Chief Scientific Officer (“CSO”), effective on the employment commencement date of his successor as CSO, which is expected to be on September 5, 2023 (the “Effective Date”). | d524173d8k.htm |
| 2023-06-22 | 8-K | 2023-06-21 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The 2023 Annual Meeting of Stockholders (the “Annual Meeting”) of Deciphera Pharmaceuticals, Inc. (the “Company”) was held on June 21, 2023. | d517350d8k.htm |
| 2023-05-03 | 8-K | 2023-05-03 | 2.02 Results of Operations and Financial Condition | 2.02 On May 3, 2023, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2023 and provided a corporate update. | d485653d8k.htm |
| 2023-02-07 | 8-K | 2023-02-07 | 2.02 Results of Operations and Financial Condition | 2.02 On February 7, 2023, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter and fiscal year ended December 31, 2022 and provided a corporate update. | d412409d8k.htm |
| 2023-01-20 | 8-K | 2023-01-19 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d426535d8k.htm |
| 2023-01-18 | 8-K | 2023-01-18 | 8.01 Other Events | 8.01 On January 18, 2023, Deciphera Pharmaceuticals, Inc. (the “Company”) filed a preliminary prospectus supplement with the Securities and Exchange Commission under its effective shelf registration statement on Form S-3 (Registration No. 333-266523) (the “Preliminary Prospectus Supplement”) in connection with a proposed registered underwritten public offering of common stock. | d431009d8k.htm |
| 2023-01-03 | 8-K | 2023-01-03 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On January 3, 2023, Deciphera Pharmaceuticals, Inc. (the “Company”) disclosed that it had a preliminary unaudited amount of net product revenue of approximately $36 million for the fourth quarter ended December 31, 2022, and approximately $134 million for the full year ended December 31, 2022. 7.01 The information provided in Item 2.02 above is incorporated herein by reference. | d421645d8k.htm |
| 2022-11-03 | 8-K | 2022-11-03 | 2.02 Results of Operations and Financial Condition | 2.02 On November 3, 2022, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter ended September 30, 2022 and other business highlights. | d408583d8k.htm |
| 2022-09-12 | 8-K | 2022-09-10 | 7.01 Regulation FD Disclosure | 7.01 On September 10, 2022, Deciphera Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the presentation of initial clinical study results from the ongoing single agent dose escalation portion of the Company’s Phase 1 study of DCC-3116, the Company’s investigational inhibitor of ULK1/2, in patients with advanced or metastatic tumors with a mutant RAS or RAF gene, as an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2022. | d290994d8k.htm |
| 2022-08-04 | 8-K | 2022-08-04 | 2.02 Results of Operations and Financial Condition | 2.02 On August 4, 2022, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2022 and other business highlights. | d273068d8k.htm |
| 2022-06-24 | 8-K | 2022-06-23 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The 2022 Annual Meeting of Stockholders (the “Annual Meeting”) of Deciphera Pharmaceuticals, Inc. (the “Company”) was held on June 23, 2022. | d322124d8k.htm |
| 2022-05-04 | 8-K | 2022-05-04 | 2.02 Results of Operations and Financial Condition | 2.02 On May 4, 2022, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2022 and other business highlights. | d235229d8k.htm |
| 2022-04-28 | 8-K | 2022-04-26 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d283154d8k.htm |
| 2022-04-26 | 8-K | 2022-04-26 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On April 26, 2022, Deciphera Pharmaceuticals, Inc. (“the Company”) disclosed that it had a preliminary unaudited amount of net product revenue of $29.2 million for the three months ended March 31, 2022, including $23.4 million in U.S. QINLOCK® (ripretinib) net product revenue, $5.4 million in international QINLOCK net product revenue, and $0.4 million of collaboration revenue. 8.01 On April 26, 2022, the Company delivered written notice to Jefferies LLC (“Jefferies”) that it was suspending and terminating the prospectus related to the Company’s common stock, $0.01 par value per share (the “ATM Prospectus”) issuable pursuant to the terms of the Open Market Sale AgreementSM, dated August 4, 2020 (the “Open Market Sales Agreement”), by and between the Company and Jefferies. | d264441d8k.htm |
| 2022-02-11 | 8-K | 2022-02-08 | 2.02 Results of Operations and Financial Condition | 2.02 On February 8, 2022, Deciphera Pharmaceuticals, Inc. (the “Company”) hosted an earnings call to discuss its financial results for the year and the quarter ended December 31, 2021, as well as to provide a corporate update. | d467470d8k.htm |
| 2022-02-08 | 8-K | 2022-02-08 | 2.02 Results of Operations and Financial Condition | 2.02 On February 8, 2022, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter and fiscal year ended December 31, 2021 and other business highlights. | d366307d8k.htm |
| 2022-01-24 | 8-K | 2022-01-24 | 7.01 Regulation FD Disclosure | 7.01 On January 24, 2022, Deciphera Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the presentation of results from the Company’s INTRIGUE Phase 3 clinical study at the American Society of Clinical Oncology Plenary Series Session. | d279635d8k.htm |
| 2022-01-10 | 8-K | 2022-01-10 | 7.01 Regulation FD Disclosure | 7.01 On January 10, 2022, Deciphera Pharmaceuticals, Inc. (the “Company”) issued a press release announcing corporate updates and highlighting key 2022 corporate milestones. | d200899d8k.htm |
| 2021-11-30 | 8-K | 2021-11-30 | 2.05 Costs Associated with Exit or Disposal Activities; 8.01 Other Events | 2.05 On November 30, 2021, Deciphera Pharmaceuticals, Inc. (the “Company”) approved and announced a restructuring (the “Restructuring”) to prioritize clinical development programs, streamline commercial operations and extend cash runway. 8.01 On November 30, 2021, the Company issued a press release related to the Restructuring. | d176831d8k.htm |
| 2021-11-22 | 8-K | 2021-11-19 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On November 22, 2021, Deciphera Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the European Commission (“EC”) approved QINLOCK® (ripretinib) in the European Union (“EU”) for the treatment of adult patients with advanced gastrointestinal stromal tumor (“GIST”) who have received prior treatment with three or more kinase inhibitors, including imatinib. 8.01 On November 22, 2021, the Company announced that the EC approved QINLOCK in the EU for the treatment of adult patients with GIST who have received prior treatment with three or more kinase inhibitors, including imatinib. | d258987d8k.htm |
| 2021-11-10 | 8-K | 2021-11-10 | 8.01 Other Events | 8.01 As previously announced on November 5, 2021, Deciphera Pharmaceuticals, Inc. (the “Company”) issued a press release announcing top-line results from the INTRIGUE Phase 3 clinical study of QINLOCK (ripretinib) in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib. | d234651d8k.htm |
| 2021-11-05 | 8-K | 2021-11-05 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On November 5, 2021, Deciphera Pharmaceuticals, Inc. (the “Company”) issued a press release announcing top-line results from the INTRIGUE Phase 3 clinical study of QINLOCK in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib. 8.01 On November 5, 2021, the Company announced top-line results from the INTRIGUE Phase 3 clinical study of QINLOCK in patients with GIST previously treated with imatinib. | d252692d8k.htm |
| 2021-11-02 | 8-K | 2021-11-02 | 2.02 Results of Operations and Financial Condition | 2.02 On November 2, 2021, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter ended September 30, 2021 and other business highlights. | d253727d8k.htm |
| 2021-09-29 | 8-K/A | 2021-06-23 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 As previously reported in the Original Form 8-K, in a non-binding advisory vote held at the 2021 Annual Meeting on the frequency of future Say-on-Pay Votes, the Company’s stockholders expressed their preference for a Say-on-Pay Vote to be conducted every one year. | d207939d8ka.htm |
| 2021-09-17 | 8-K | 2021-09-17 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On September 17, 2021, Deciphera Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) adopted a positive opinion recommending the approval of QINLOCK® (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (“GIST”) who have received prior treatment with three or more kinase inhibitors, including imatinib. 8.01 On September 17, 2021, the Company announced that the CHMP adopted a positive opinion recommending the approval of QINLOCK for the treatment of adult patients with GIST who have received prior treatment with three or more kinase inhibitors, including imatinib. | d224855d8k.htm |
| 2021-09-17 | 8-K | 2021-09-17 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On September 17, 2021, Deciphera Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the presentation of new clinical study results across the Company’s clinical pipeline at the European Society for Medical Oncology (“ESMO”) Congress 2021. 8.01 On September 17, 2021, the Company presented new clinical study results across the Company’s clinical pipeline in e-poster presentations at the ESMO Congress 2021. | d203720d8k.htm |
| 2021-08-03 | 8-K | 2021-08-03 | 2.02 Results of Operations and Financial Condition | 2.02 On August 3, 2021, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2021 and other business highlights. | d184237d8k.htm |
| 2021-06-25 | 8-K | 2021-06-23 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The 2021 Annual Meeting of Stockholders of Deciphera Pharmaceuticals, Inc. (the “Company”), was held on June 23, 2021 (the “Annual Meeting”). | d148791d8k.htm |
| 2021-05-04 | 8-K | 2021-05-04 | 2.02 Results of Operations and Financial Condition | 2.02 On May 4, 2021, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2021 and other corporate updates. | d234603d8k.htm |
| 2021-03-31 | 8-K | 2021-03-31 | 7.01 Regulation FD Disclosure | 7.01 On March 31, 2021, Deciphera Pharmaceuticals, Inc., or the Company, and its Greater China partner, Zai Lab, issued the press release attached hereto as Exhibit 99.1. | d125771d8k.htm |
| 2021-02-09 | 8-K | 2021-02-09 | 2.02 Results of Operations and Financial Condition | 2.02 On February 9, 2021, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter and fiscal year ended December 31, 2020 and other business highlights. | d129497d8k.htm |
| 2021-01-11 | 8-K | 2021-01-11 | 7.01 Regulation FD Disclosure | 7.01 On January 11, 2021, Deciphera Pharmaceuticals, Inc., or the Company, issued the press release attached hereto as Exhibit 99.1. | d899244d8k.htm |
| 2020-11-30 | 8-K | 2020-11-30 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On November 30, 2020, Deciphera Pharmaceuticals, Inc. (the “Company”) announced the completion of its target enrollment in the INTRIGUE Phase 3 clinical study evaluating the efficacy and safety of QINLOCK® compared to sunitinib in patients with second-line gastrointestinal stromal tumor (“GIST”). 8.01 On November 30, 2020, the Company announced the completion of its target enrollment in the INTRIGUE Phase 3 clinical study evaluating the efficacy and safety of QINLOCK compared to sunitinib in patients with second-line GIST. | d96913d8k.htm |
| 2020-11-12 | 8-K | 2020-11-11 | 8.01 Other Events | 8.01 On November 11, 2020, Deciphera Pharmaceuticals, Inc. announced the presentation of preliminary results from the ongoing Phase 1/2 study of DCC-3014, a highly selective, oral, investigational switch-control kinase inhibitor of CSF1R, in patients with tenosynovial giant cell tumor. | d851864d8k.htm |
| 2020-11-05 | 8-K | 2020-11-05 | 2.02 Results of Operations and Financial Condition | 2.02 On November 5, 2020, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter ended September 30, 2020 and other business highlights. | d36169d8k.htm |
| 2020-08-04 | 8-K | 2020-08-04 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d935260d8k.htm |
| 2020-08-04 | 8-K | 2020-08-04 | 2.02 Results of Operations and Financial Condition | 2.02 On August 4, 2020, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2020. | d35635d8k.htm |
| 2020-06-12 | 8-K | 2020-06-10 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 5.03 On June 10, 2020, the Board of Directors (the “Board”) of Deciphera Pharmaceuticals, Inc. (the “Company”) amended and restated the Company’s Amended and Restated By-laws (as amended and restated, the “Amended and Restated By-laws”) in order to amend Section 8 of Article VI to designate the United States District Court for the District of Massachusetts as the exclusive jurisdiction for any litigation arising under the Securities Act of 1933, as amended. 5.07 The Company held its annual meeting (the “Annual Meeting”) of stockholders on June 10, 2020. | d935605d8k.htm |
| 2020-05-15 | 8-K | 2020-05-15 | 8.01 Other Events | 8.01 On May 15, 2020, Deciphera Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration approved the Company’s new drug application for QINLOCK™ (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib. | d934588d8k.htm |
| 2020-05-05 | 8-K | 2020-05-05 | 2.02 Results of Operations and Financial Condition | 2.02 On May 5, 2020, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2020. | d925557d8k.htm |
| 2020-03-09 | 8-K | 2020-03-09 | 2.02 Results of Operations and Financial Condition | 2.02 On March 9, 2020, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter and fiscal year ended December 31, 2019. | d836594d8k.htm |
| 2020-02-14 | 8-K | 2020-02-12 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On February 13, 2020, Deciphera Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Piper Sandler & Co. and Jefferies LLC, as representatives of the several underwriters (the “Underwriters”), relating to the registered public offering (the “Offering”) of 3,181,818 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at a price to the public of $55.00 per share. 8.01 On February 12, 2020, the Company issued a press release announcing that it had commenced the Offering. | d889175d8k.htm |
| 2020-02-12 | 8-K | 2020-02-12 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 Deciphera Pharmaceuticals, Inc. (“We,” the “Company,” or “Deciphera”) is currently in the process of finalizing our financial results for the three months and year ended December 31, 2019. 8.01 Deciphera is filing information for the purpose of supplementing and updating certain aspects of the description of its business from that described under the heading, “Item 1. | d793776d8k.htm |
| 2020-01-13 | 8-K | 2020-01-13 | 7.01 Regulation FD Disclosure | 7.01 On January 13, 2020, Deciphera Pharmaceuticals, Inc., or the Company, issued the press release attached hereto as Exhibit 99.1. | d861944d8k.htm |
| 2019-12-16 | 8-K | 2019-12-16 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On December 16, 2019, Deciphera Pharmaceuticals, Inc., or the Company, issued a press release announcing submission of a New Drug Application to the U.S. FDA for ripretinib in patients with advanced gastrointestinal stromal tumors. 8.01 On December 16, 2019, the Company announced the submission of a New Drug Application, or NDA, to the U.S. Food and Drug Administration (FDA) for ripretinib, the Company’s investigational broad-spectrum KIT and PDGFRα inhibitor, for the treatment of patients with advanced gastrointestinal stromal tumors (GIST) who have received prior treatment with imatinib, sunitinib and regorafenib. | d839453d8k.htm |
| 2019-12-04 | 8-K | 2019-12-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (d) On December 4, 2019, the Board of Directors (the “Board”) of Deciphera Pharmaceuticals, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Ron Squarer to the Board, effective December 4, 2019. | d827067d8k.htm |
| 2019-11-26 | 8-K | 2019-11-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (d) On November 25, 2019, the Board of Directors (the “Board”) of Deciphera Pharmaceuticals, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Frank S. Friedman to the Board, effective November 25, 2019. | d840866d8k.htm |
| 2019-11-13 | 8-K | 2019-11-13 | 7.01 Regulation FD Disclosure | 7.01 On November 13, 2019, Deciphera Pharmaceuticals, Inc., or the Company, issued a press release announcing preliminary data from its ongoing Phase 1 study of DCC-3014, an oral inhibitor of CSF1R, including data in patients with diffuse-type tenosynovial giant cell tumor. | d834294d8k.htm |
| 2019-11-04 | 8-K | 2019-11-04 | 2.02 Results of Operations and Financial Condition | 2.02 On November 4, 2019, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter ended September 30, 2019. | d830272d8k.htm |
| 2019-10-29 | 8-K | 2019-10-28 | 7.01 Regulation FD Disclosure | 7.01 On October 28, 2019, Deciphera Pharmaceuticals, Inc. (the “Company”) issued a press release announcing updated data for two of its programs, namely (1) its Phase 1b/2 study of rebastinib (DCC-2036) in combination with paclitaxel: preliminary safety, efficacy, pharmacokinetics and pharmacodynamics in patients with advanced or metastatic solid tumors and (2) preclinical studies with DCC-3116, an ULK kinase inhibitor designed to inhibit autophagy as a potential strategy to address mutant RAS cancers. | d816474d8k.htm |
| 2019-09-30 | 8-K | 2019-09-30 | 7.01 Regulation FD Disclosure | 7.01 On September 30, 2019, Deciphera Pharmaceuticals, Inc. (the “Company”) announced the presentation of results from its INVICTUS pivotal Phase 3 study in patients with advanced gastrointestinal stromal tumors presented in an oral presentation at the European Society of Medical Oncology 2019 Congress. | d809273d8k.htm |
| 2019-08-15 | 8-K | 2019-08-13 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On August 14, 2019, Deciphera Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Piper Jaffray & Co. and Jefferies LLC, as representatives of the several underwriters (the “Underwriters”), relating to the registered public offering (the “Offering”) of 10,810,810 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), at a price to the public of $37.00 per share. 8.01 On August 13, 2019, the Company issued a press release announcing that it had commenced the Offering. | d774095d8k.htm |
| 2019-08-13 | 8-K | 2019-08-13 | 8.01 Other Events | 8.01 On August 13, 2019, Deciphera Pharmaceuticals, Inc. (the “Company” or “we”) announced positive top-line data from its INVICTUS pivotal Phase 3 clinical study of ripretinib, a broad-spectrum KIT and PDGFRα inhibitor, in patients with fourth-line and fourth-line plus gastrointestinal stromal tumor, or GIST. | d791955d8k.htm |
| 2019-08-02 | 8-K | 2019-08-02 | 2.02 Results of Operations and Financial Condition | 2.02 On August 2, 2019, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2019. | d733165d8k.htm |
| 2019-07-08 | 8-K | 2019-07-08 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 8, 2019, the Board of Directors (the “Board”) of Deciphera Pharmaceuticals, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Susan L. Kelley, M.D. to the Board, effective July 8, 2019. | d744648d8k.htm |
| 2019-06-13 | 8-K | 2019-06-11 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 – Submission of Matters to a Vote of Security Holders. | d714734d8k.htm |
| 2019-06-11 | 8-K | 2019-06-10 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d887657d8k.htm |
| 2019-05-09 | 8-K | 2019-05-09 | 2.02 Results of Operations and Financial Condition | 2.02 On May 9, 2019, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2019. | d745557d8k.htm |
| 2019-05-03 | 8-K | 2019-04-29 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth above in Item 1.01 of this Current Report on Form 8-K regarding the Amendment is incorporated into this Item 2.03 by reference. | d733314d8k.htm |
| 2019-03-14 | 8-K | 2019-03-14 | 2.02 Results of Operations and Financial Condition | 2.02 On March 14, 2019, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter and fiscal year ended December 31, 2018. | d720514d8k.htm |
| 2019-03-04 | 8-K | 2019-03-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 4, 2019, Dr. Michael Taylor notified Deciphera Pharmaceuticals, Inc. (the “Company”) of his resignation from his position as President and Chief Executive Officer, effective March 18, 2019 (the “Effective Date”). | d718027d8k.htm |
| 2019-02-22 | 8-K | 2019-02-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 15, 2019, Liam Ratcliffe, M.D., Ph.D. provided Deciphera Pharmaceuticals, Inc. (the “Company”) with notice of his resignation from the Board of Directors of the Company, effective as of February 22, 2019. | d698637d8k.htm |
| 2018-11-08 | 8-K | 2018-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2018, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter ended September 30, 2018. | d641272d8k.htm |
| 2018-10-19 | 8-K | 2018-10-19 | 8.01 Other Events | 8.01 On October 19, 2018, Deciphera Pharmaceuticals, Inc. (the “Company”) announced updated preliminary results from its ongoing Phase 1 clinical study of DCC-2618, the company’s broad-spectrum KIT and PDGFRα inhibitor, in patients with gastrointestinal stromal tumors (“GIST”) at a presentation at the European Society of Medical Oncology 2018 Congress (“ESMO 2018”). | d640111d8k.htm |
| 2018-08-07 | 8-K | 2018-08-07 | 2.02 Results of Operations and Financial Condition | 2.02 On August 7, 2018, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2018. | d597912d8k.htm |
| 2018-06-04 | 8-K | 2018-06-04 | 8.01 Other Events | 8.01 On June 4, 2018, Deciphera Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the commencement of an underwritten public offering of common stock of the Company, par value $0.01 per share, pursuant to a registration statement on Form S-1 (the “Registration Statement”) filed by the Company with the Securities and Exchange Commission, or the SEC, on June 4, 2018. | d594238d8k.htm |
| 2018-06-04 | 8-K | 2018-06-02 | 7.01 Regulation FD Disclosure | 7.01 On June 2, 2018, Deciphera Pharmaceuticals, Inc. (the “Company”) issued the press release attached hereto as Exhibit 99.1. | d596074d8k.htm |
| 2018-05-31 | 8-K | 2018-05-29 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth above in Item 1.01 of this Current Report on Form 8-K regarding the Lease is incorporated into this Item 2.03 by reference. | d590049d8k.htm |
| 2018-05-21 | 8-K | 2018-05-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 – Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers. 5.07 – Submission of Matters to a Vote of Security Holders. | d591883d8k.htm |
| 2018-05-08 | 8-K | 2018-05-08 | 2.02 Results of Operations and Financial Condition | 2.02 On May 8, 2018, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2018. | d583312d8k.htm |
| 2018-03-28 | 8-K | 2018-03-28 | 2.02 Results of Operations and Financial Condition | 2.02 On March 28, 2018, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter and fiscal year ended December 31, 2017. | d558216d8k.htm |
| 2017-11-14 | 8-K | 2017-11-14 | 2.02 Results of Operations and Financial Condition | 2.02 On November 14, 2017, Deciphera Pharmaceuticals, Inc. announced its financial results for the quarter ended September 30, 2017. | d688878d8k.htm |
| 2017-10-05 | 8-K | 2017-10-02 | 3.02 Unregistered Sales of Equity Securities; 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 3.02 On October 2, 2017, Deciphera Pharmaceuticals, Inc. (the “Company”) closed its initial public offering (“IPO”), immediately prior to which the Company issued to direct and indirect equityholders of Deciphera Pharmaceuticals, LLC an aggregate of 24,425,190 shares of common stock, par value $0.01 per share, of the Company in exchange for, directly and indirectly, all of the outstanding preferred shares of Deciphera Pharmaceuticals, LLC (the “Exchange”). 3.03 See the discussion set forth in Item 5.03 of this Current Report on Form 8-K, which discussion is incorporated herein by reference. 5.03 On October 2, 2017, immediately prior to the closing of the IPO, the Company amended and restated its certificate of incorporation (the “Certificate of Incorporation”), which was filed with the Secretary of State of the State of Delaware on September 29, 2017. | d462461d8k.htm |